Zhang Kai, Wang Yan-Yan, Xu Yao, Zhang Li, Zhu Jiang, Si Peng-Chao, Wang Ya-Wen, Ma Rong
Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, People's Republic of China.
Health Management Center, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, People's Republic of China.
Pathol Res Pract. 2021 Jun;222:153458. doi: 10.1016/j.prp.2021.153458. Epub 2021 Apr 29.
Differentially expressed microRNAs (miRNAs) in the blood of breast cancer patients may serve as diagnostic biomarkers.
In this study, miRNA microarray of the blood of breast cancer patients and healthy controls was performed. Candidate differentially expressed miRNAs were further verified by real-time polymerase chain reaction in 68 breast cancer patients and 13 healthy controls.
Six upregulated blood miRNAs (miR-26b-5p, miR-106b-5p, miR-142-3p, miR-142-5p, miR-185-5p, and miR-362-5p) were identified in breast cancer patients. These six miRNAs could discriminate breast cancer patients from healthy controls, with areas under the receiver operating characteristic curve (AUCs) of 0.8891, 0.8158, 0.8529, 0.8507, 0.9050, and 0.9333, respectively. Bioinformatic analysis showed that the six miRNAs were potentially involved in numerous cancer-related pathways, including the mitogen-activated protein kinase signaling pathway, nuclear factor-kappa B signaling pathway, and the transforming growth factor-beta signaling pathway. Importantly, two miRNAs (miR-185-5p and miR-362-5p) were used to construct a two-miRNA panel by logistic regression. The two-miRNA panel displayed a better diagnostic performance than each of the miRNAs alone, with a higher AUC (0.957), sensitivity (92.65 %), and specificity (92.31 %). Additionally, the high expression of the six miRNAs or the two-miRNA panel was associated with poor prognosis of breast cancer.
We identified six upregulated miRNAs and a two-miRNA panel in the blood as potential biomarkers for the diagnosis and prognosis of breast cancer.
乳腺癌患者血液中差异表达的微小RNA（miRNA）可作为诊断生物标志物。
在本研究中，对乳腺癌患者和健康对照者的血液进行了miRNA微阵列检测。通过实时聚合酶链反应在68例乳腺癌患者和13例健康对照者中进一步验证候选差异表达的miRNA。
在乳腺癌患者中鉴定出6种上调的血液miRNA（miR-26b-5p、miR-106b-5p、miR-142-3p、miR-142-5p、miR-185-5p和miR-362-5p）。这6种miRNA能够区分乳腺癌患者和健康对照者，其受试者工作特征曲线下面积（AUC）分别为0.8891、0.8158、0.8529、0.8507、0.9050和0.9333。生物信息学分析表明，这6种miRNA可能参与众多癌症相关通路，包括丝裂原活化蛋白激酶信号通路、核因子-κB信号通路和转化生长因子-β信号通路。重要的是，通过逻辑回归使用两种miRNA（miR-185-5p和miR-362-5p）构建了一个双miRNA组合。该双miRNA组合显示出比单独的每种miRNA更好的诊断性能，具有更高的AUC（0.957）、灵敏度（92.65%）和特异性（92.31%）。此外，这6种miRNA或双miRNA组合的高表达与乳腺癌的不良预后相关。
我们在血液中鉴定出6种上调的miRNA和一个双miRNA组合，作为乳腺癌诊断和预后的潜在生物标志物。
